Scientists investigate Histidine's role in boosting immunotherapy for colorectal cancer
NCT ID NCT07586293
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study looks at how histidine, a common amino acid, and its transporter SLC15A3 influence colorectal cancer's sensitivity to immunotherapy. Researchers will analyze tumor tissue and blood samples from 150 patients to understand why some cancers resist treatment. The goal is to find new targets that could improve immunotherapy effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could point toward new ways to make colorectal cancer more responsive to immunotherapy.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test any new therapy. Results may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?